Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.86 |
| ▸ | TTR | P02766 | 3/20 | 0.86 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.86 |
| ▸ | CA12 | O43570 | 2/20 | 0.86 |
| ▸ | CA1 | P00915 | 2/20 | 0.86 |
| ▸ | CA2 | P00918 | 2/20 | 0.86 |
| ▸ | CA3 | P07451 | 2/20 | 0.86 |
| ▸ | CA4 | P22748 | 2/20 | 0.86 |
| ▸ | CA6 | P23280 | 2/20 | 0.86 |
| ▸ | CA5A | P35218 | 2/20 | 0.86 |
| ▸ | CA7 | P43166 | 2/20 | 0.86 |
| ▸ | CA9 | Q16790 | 2/20 | 0.86 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.86 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.86 |
| ▸ | APP | P05067 | 2/20 | 0.86 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.86 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.86 |
| ▸ | MAPT | P10636 | 2/20 | 0.86 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.86 |
| ▸ | DPP4 | P27487 | 2/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Caffeic Acid SCHEMBL29447135 | 0.93 | KDM4E (1.00) | KDM4ETTRHSD17B10CA12CA1 | |
| Caffeic Acid SCHEMBL29353048 | 0.93 | KDM4E (1.00) | KDM4ETTRHSD17B10CA12CA1 | |
| Caffeic Acid SCHEMBL30050844 | 0.93 | KDM4E (1.00) | KDM4ETTRHSD17B10CA12CA1 | |
| Caffeic Acid SCHEMBL30501140 | 0.93 | KDM4E (1.00) | KDM4ETTRHSD17B10CA12CA1 | |
| Caffeic Acid SCHEMBL7064846 | 0.93 | KDM4E (1.00) | KDM4ETTRHSD17B10CA12CA1 | |
| Caffeic Acid SCHEMBL3682144 | 0.93 | KDM4E (1.00) | KDM4ETTRHSD17B10CA12CA1 | |
| Caffeic Acid SCHEMBL1262229 | 0.93 | KDM4E (1.00) | KDM4ETTRHSD17B10CA12CA1 | |
| Caffeic Acid SCHEMBL23358 | 0.93 | KDM4E (1.00) | KDM4ETTRHSD17B10CA12CA1 | |
| Caffeic Acid SCHEMBL21114743 | 0.93 | KDM4E (1.00) | KDM4ETTRHSD17B10CA12CA1 | |
| Caffeic Acid SCHEMBL23359 | 0.93 | KDM4E (1.00) | KDM4ETTRHSD17B10CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116375685-B | Fasudil derivative and preparation method and application thereof | 沈阳药科大学 | 2023-12-12 | — | — | CN | disclosed |
| CN-116375685-A | Fasudil derivative and preparation method and application thereof | 沈阳药科大学 | 2023-07-04 | — | — | CN | disclosed |
| CN-115894248-A | Caffeic acid nitric oxide donor derivative and preparation method and application thereof | 深圳枫语生物医药科技有限公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-4069208-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | Flagship Pioneering Innovations V, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| US-20220296555-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2022-09-22 | — | — | US | disclosed |
| CN-105188728-B | Peptides and peptide-active substance conjugates for renal targeting | 默克专利股份有限公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-105188729-B | Conjugates for protection against nephrotoxic active substances | 默克专利股份有限公司 | 2021-11-09 | — | — | CN | disclosed |
| WO-2021113635-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| CN-106414402-A | Aryloyl(oxy or amino)pentafluorosulfanylbenzene compound, pharmaceutically acceptable salt thereof, and prodrugs thereof | 宇部兴产株式会社 | 2017-02-15 | — | — | CN | disclosed |
| CN-105188728-A | Peptides and peptide-active ingredient-conjugate for renal drug-targeting | MERCK PATENT GMBH | 2015-12-23 | — | — | CN | disclosed |
| CN-105188729-A | Conjugates for protection from nephrotoxic active substances | MERCK PATENT GMBH | 2015-12-23 | — | — | CN | disclosed |
| WO-2000063152-A1 | ACETYLATED AND RELATED ANALOGUES OF CHICORIC ACID AS HIV INTEGRASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296555-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FABP1, LIPC, CPT1A | KDM4E 3280/4885TTR 859/4885HSD17B10 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.